Q-omics provides the consensus-scored HCG4B profile across patient tissues and cancer cell-line models. HCG4B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HCG4B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, HCG4B RNA expression shows 16,947 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRC, and THYM as cancer lineages where HCG4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCG4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCG4B survival associations across molecular data types. HCG4B RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCG4B RNA expression–survival associations across cancer types. High HCG4B expression shows unfavorable associations in LGG, COAD and LAML, but favorable associations in BLCA, SKCM and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for HCG4B RNA expression.
This table summarizes HCG4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HCG4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCG4B shows lower tumor expression in KICH, BRCA and THCA and higher tumor expression in KIRC, HNSC and LUAD. The KIRC box plot shows higher HCG4B RNA expression in tumor versus normal tissue (log2 FC = +0.899, t-test p < 0.001).
This table shows molecular features associated with HCG4B in patient tissues and cancer cell lines. In patient samples, HCG4B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, HCG4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
